Follow us on Twitter
twitter icon@FreshPatents


Urogenital patents

      

This page is updated frequently with new Urogenital-related patent applications.




 Lactic acid bacteria as probiotic strains and compositions containing same patent thumbnailLactic acid bacteria as probiotic strains and compositions containing same
Useful probiotics have been selected among lactic acid bacteria strains of the genus l. Acidophilus, l.
Probioswiss Ag


 Device for treating the female urogenital tract patent thumbnailDevice for treating the female urogenital tract
The invention relates to a device for treating the female urogenital tract and is characterized in that the device comprises a covering device (1) for the urogenital region at least in the region of the vulva, the vagina and the urethra; and in that the covering device is treated substantially fully with an antimicrobial and/or antiseptic substance preventing the migration of bacteria into the urogenital tract.. .
Tecuro Ag


 Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder patent thumbnailHerbal compositions for the prevention or treatment of urinary incontinence and overactive bladder
Provided in one embodiment is an herbal compositions for the prevention or treatment of urogenital system disorders including urinary incontinence, overactive bladder, enuresis, benign prostatic hyperplasia, nocturia, cystitis, urinary calculi, or a urinary tract infection. Specifically one embodiment provides compositions that contain crateva nurvala, equisetum arvense, and lindera aggregata and methods of use thereof..

 Compositions for treatment of atrophic vaginitis, peri- and post-menopausal dyspareunia, and/or oophorectomized females and treatment methods therewith patent thumbnailCompositions for treatment of atrophic vaginitis, peri- and post-menopausal dyspareunia, and/or oophorectomized females and treatment methods therewith
Compositions for topical administration to a urogenital area and/or in a vagina are disclosed. The compositions includes a therapeutically effective amount of a selective estrogen receptor modulator (serm), an intracellular carrier for carrying the serm into a cell, and a therapeutically effective amount of a cellular anti-inflammatory agent.
Durga Enterprises, Llc


 Chromosomal assessment to diagnose urogenital malignancy in dogs patent thumbnailChromosomal assessment to diagnose urogenital malignancy in dogs
This invention is directed to a method of diagnosing bladder cancer in dogs.. .
North Carolina State University


 Methods for treating radiation induced gastrointestinal tract injury patent thumbnailMethods for treating radiation induced gastrointestinal tract injury
Methods of preventing, ameliorating and/or treating radiation induced gastrointestinal tract injury comprising the administration of a therapeutically effective amount of mesna to a patient are provided. Methods for preventing, treating and/or ameliorating gastrointestinal tract injury induced by radiation therapy, alone or in combination with other therapies for diseases or conditions such as gastrointestinal malignancies, urogenital malignancies, gynecologic malignancies, and osteogenic and other sarcomatous malignancies in which pelvic structures are involved..
Rdd Pharma Ltd.


 Methods of detecting chlamydia and gonorrhea and of screening for infection/inflammation based on genomic copy number patent thumbnailMethods of detecting chlamydia and gonorrhea and of screening for infection/inflammation based on genomic copy number
Compositions and methods for detecting chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) are provided. The present invention also provides methods and compositions for screening for infection/inflammation based on genomic copy number.
Cepheid


 Integrated ultrasound, oct, pa and/or florescence imaging endoscope for diagnosing cancers in gastrointestinal, respiratory, and urogenital tracts patent thumbnailIntegrated ultrasound, oct, pa and/or florescence imaging endoscope for diagnosing cancers in gastrointestinal, respiratory, and urogenital tracts
A multimodality imaging system including ultrasound, optical coherence tomography (oct), photoacoustic (pa) imaging, florescence imaging and endoscopic catheter for imaging inside the gastrointestinal tract with real-time automatic image co-registration capability, including: an ultrasound subsystem for imaging; an optical coherence tomography (oct) subsystem for imaging, a pa microscopy or tomography subsystem for imaging and a florescence imaging subsystem for imaging. An invasive interventional imaging device is included with an instrumentality to take a tissue biopsy from a location visible on the ultrasound subsystem for imaging, on the optical coherence tomography (oct) subsystem for imaging, photoacoustic (pa) subsystem for imaging and florescence subsystem for imaging.
University Of Southern California


 Pharmaceutical compositions comprising sodium meta arsenite for treatment of multiple myeloma patent thumbnailPharmaceutical compositions comprising sodium meta arsenite for treatment of multiple myeloma
The present application relates to pharmaceutical compositions and methods for treatment of urogenital diseases and bone metastasis in a human, which pharmaceutical composition contains an effective amount of arsenous acid alkaline or earth alkaline metal salt and/or a pharmaceutically acceptable adjuvant. According to the present invention, the alkaline arsenous acid metal salt is sodium meta-arsenita (aso2na) or potassium meta-arsenite (aso2k).
Kominox, Inc.


 Prevention, treatment, and amelioration of radiation induced enteritis patent thumbnailPrevention, treatment, and amelioration of radiation induced enteritis
The present invention provides a new method of ameliorating and/or treating enteritis induced by radiation therapy, alone or in combination with other therapies, for the treatment oil for example, gastrointestinal malignancies, including colorectal, appendiceal, anal, or small bowel cancers; urogenital malignancies, including prostate, bladder, testicular, or penile cancers; gynecologic malignancies, including cervical, endometrial, ovarian, vaginal, or vulvar cancers; or osteogenic and other sarcomatous malignancies in which pelvic structures are involved, comprising the administration of a therapeutically effective amount of balsalazide to a patient in need thereof. .

Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate

The present invention relates to a pharmaceutical composition which comprises progestogens, preferably drospirenone, estrogens, preferably ethinylestradiol and 5-methyl-(6s)-tetrahydrofolate, can be employed as oral contraceptive and moreover prevents disorders caused by folate deficiency in the consumers, in particular cardiovascular disorders and, after conception of the embryo, congenital malformations caused by folate deficiency such as, for example, neural tube defects, ventricular valve defects, urogenital defects, and cleft lip, jaw and palate, without masking the symptoms of vitamin b12 deficiency, and at the same time even in the case of homozygous or heterozygous polymorphism of methylenetetrahydrofolate reductase facilitates unimpaired utilizability of the folate component 5-methyl-(6s)-tetrahydrofolate by the body and thus its biological activity for preventing the abovementioned congenital malformations caused by folate deficiency. In addition, a prolonged protective effect is maintained after discontinuation of the contraceptive..
Bayer Intellectual Property Gmbh

Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same

The invention relates to a nanoproduct useful in prophylaxis and medicine, both human and veterinary as well as to a medical use of the same. The invention discloses lactobacillus reuteri dan080 strain with deposit number dsm 15693 for use in medicine.

P2x7 modulators

The present invention is directed to a compound of formula (i) or (ia) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) or (ia) and methods comprising administering of compounds of formula (i) or (ia) for treating rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv

P2x7 modulators

The present invention is directed to a compound of formula (i) formula (i) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) and methods comprising administering to a subject at least one compound selected from compounds of formula (i) for treating diseases mediated by p2x7 receptor activity, such as rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv

Methods of detecting chlamydia and gonorrhea and of screening for infection/inflammation based on genomic copy number

Compositions and methods for detecting chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) are provided. The present invention also provides methods and compositions for screening for infection/inflammation based on genomic copy number.
Cepheid

Oral combination for the prevention and treatment of bladder, pelvic and urogenital apparatus pathologies

The invention describes a pharmaceutical association of active ingredients comprising: curcumin, quercetin, chondroitin sulfate and hyaluronic acid, used for the prevention or treatment of bladder, pelvic and urogenital apparatus pathologies.. .
Altergon S.a.

Pharmaceutical composition

Pharmaceutical compositions useful in the treatment of sexual and urogenital dysfunctions such as dyspareunia, vulvodynia, vaginismus, vestibulitis and anal fistulas.. .
Dipharma Francis S.r.l.

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

X, y, z, r, r1, r2, r3, r′3 r4, r5, r6, r7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

X, y, z, r, r1, r2, r3, r′3 r4, r5, r6, r7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

X, y, z, r, r1, r2, r3, r′3 r4, r5, r6, r7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

X, y, z, r, r1, r2, r3, r′3 r4, r5, r6, r7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

X, y, z, r, r1, r2, r3, r′3 r4, r5, r6, r7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .

Markers of the male urogenital tract

Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides, encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention.
Mount Sinai Hospital

Use of thiosulfate to potentiate the anti-pathogenic effect of lactobacilli

The present disclosure relates to the use of thiosulfate to potentiate the anti-pathogenic effect of lactobacilli bacteria, the thiosulfate being in a quantity of at least 100 mg for 107 to 1010 cfu of lactobacilli. The disclosure also relates to a pharmaceutical composition including at least 100 mg of thiosulfate per gram, in combination with a lactobacillus crispatus strain, and to its use in the treatment of urogenital infections such as vaginosis, candidosis and urinary tract infections..
Probionov

Vaginal suppository comprising lactic acid

It also relates to the use of such a suppository for the production of a medicament for the treatment and/or prophylaxis of disorders in the urogenital tract as well as to a method for the treatment and/or prophylaxis of disorders in the urogenital tract.. .

Novel steroidal cyp17 inhibitors/antiandrogens

Wherein: the abcd ring structure is the nucleus of a steroid, or an analog thereof; x is a group capable of coordinating a heme group of cyp17, and y is an hydroxyl functionality, a suitable ester, or a prodrug group, for the treatment of urogenital and/or androgen-related cancers, such as castration-resistant prostate cancer. The invention provides methods of synthesizing new chemical entities and methods of using the same in treating urogenital and/or androgen-related cancers..

Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens

Prodrugs of c-17-heterocyclic-steroidal drugs providing improved oral bioavailability and phamacokinetics are described. The drugs are inhibitors of human cyp 17 enzyme, as well as potent antagonists of both wild type and mutant androgen receptors (ar), and are useful for the treatment of urogenital and/or androgen-related cancers, diseases and/or conditions, such as human prostate cancer, breast cancer, and prostate hyperplasia.
Tokai Pharmaceuticals, Inc.

Intrauterine system for use in medical treatment

An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound.

Methods and tools for the diagnosis and prognosis of urogenital cancers

The present invention provides a microarray useful as a tool in the diagnosis and/or prognosis of certain types of cancers, particularly urogenital cancers. The microarray can include a plurality of genomic regions represented thereon, the genomic regions corresponding to regions wherein alterations, such as copy number aberrations, at such locations correlate to specific, identifiable cancers, particularly prostate, renal, or bladder tumors.

Methods and systems for treating heart instability

Systems and methods define an index of risk for cardiac disease by detecting cellular derangements that may lead to cardiomyopathy, heart rhythm disorders or ischemic heart disease. The markers include fluctuations or abnormal rate-behavior of electrical, mechanical or other measurable biosignals.

Wrap-around canine hunting vest with lower abdomen protection

A canine ventral chest and lower abdomen protection garment is disclosed for protection of a canine from impact with an obstacle. The garment mounts to the canine via a collar, a thoracic strap and a lumbar strap for a secure placement.

System and anchoring support material to tissue

A method of anchoring a support material to tissue includes forming an incision in a urogenital triangle of a patient for access to a pelvis of the patient; inserting a body portion of an anchor into a lumen in a cannula and having a spine portion of the anchor extending radially out of a wall of the cannula; and inserting a leading end of the cannula and the anchor into the incision. The method includes pushing the leading end of the cannula into periosteum tissue of the pelvis; engaging the spine portion of the anchor with the periosteum tissue; withdrawing the leading end of the cannula from the incision and leaving the anchor engaged in the periosteum tissue; and securing the support material to a suture that is attached to the anchor.

Targeted liposomes

The present invention is in the field of drug delivery, and specifically, cationic liposome-based drug delivery. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of liposomes to tumors, including brain tumors.

Tigecycline crystalline hydrate and preparation method therefor and use thereof

Provided are a tigecycline crystalline hydrate, and a preparation method therefor and use thereof. The crystalline hydrate has high stability for storage, and is used for the manufacture of a medicament for treating or preventing the infection of respiratory system, hepatobiliary system, facial features, urogenital system, bone and joint, skin and soft tissue and endocarditis, septicemia, meningitis caused by susceptible strains of gram-positive or gram-negative bacteria, anaerobic bacteria, chlamydia, and mycoplasma in human or animal..

Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers

Said nanocomplexes are useful, and showed to be efficient in vivo, as pharmaceutical formulations of biphosphonates for the treatment or prevention of tumor growth and/or metastasis. Tumors can be solids and/or haematological such as prostate, lung, head/neck, colon, liver, breast, pancreas, kidneys, bladder, male and female urogenital tract, bones, multiple myeloma, primitive and secondary tumours of the central nervous system and lymphomas..

Pharmacological preparation for topical use containing npalmitoyl-vanillamide

The present invention relates to topical preparations containing n-palmitoyl-vanillamide having hyperalgesic activity. In particular, the invention relates to n-palmitoyl-vanillamide for use in the treatment of pathologies selected from: post-herpetic neuralgia, neuralgia of trigeminus, occipital neuralgia, dental neuralgia, glottopharyngeal neuralgia, uremic neuralgia, diabetic neuralgia, headache of different origin, neuropathic itch, neurogenic itch, uremic itch, vulvodinia, vulvar vestibulitis, ano-rectal pain and itch, balano-preputial pain and itch, painful urogenital disorders of dogs and cats, psoriasis-associated pruritus and pain, itching skin diseases (e.g.

Protein stabilized probiotics and personal care products

The present invention also relates to the personal care product being a feminine care product particularly aimed at female urogenital health to treat or prevent vaginal infections. Oral and sinus infections, however, may also be benefited by the composition..



Urogenital topics:
  • Urogenital
  • Pharmaceutically Acceptable Salt
  • Neurological
  • Intestinal Diseases
  • Gastrointestinal
  • Gastrointestinal Disease
  • Pharmaceutically Acceptable Salts
  • Psychiatric
  • Pathologic
  • Gastrointestinal Diseases
  • Localization
  • Binding Agent
  • Polynucleotide
  • Nucleotide
  • Cognitive Disorders


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Urogenital for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Urogenital with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3815

    file did exist - file did put1699

    3 - 1 - 37